Big 4 - Breast Cancer Flashcards

1
Q

What is the UK breast cancer risk and what factor is incidence related to?

What is survival like?

A
  • the UK lifetime breast cancer risk is 1 in 8 (12%)
  • survival is increasing with a 10 year survival rate of 80%
  • the incidence is age related, with >50% of cases occurring in women >50
    • less than 5% of cases occur in women <40
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How can the risk factors for breast cancer be subdivided?

A
  • there is not a single more prominent cause of breast cancer (unlike lung)

Uninterrupted oestrogen exposure:

  • early menarche and/or late menopause
  • nulliparity / first child at older age
  • use of HRT (particularly combined)
  • obesity
  • combined oral contraceptive pill

Lifestyle:

  • alcohol consumption (>14 units / week)
  • smoking
  • diet

Genetic:

  • BRCA1
  • BRCA2
  • P53

Other:

  • chest wall / mediastinal radiotherapy
  • dense breast tissue
  • personal / family history
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What factors might make you question whether someone has a gene that could result in breast cancer?

A

when asking about family history, note:

  • cluster of cases in the family that are also affecting younger people
  • history of ovarian cancer and bilateral breast cancer
  • history of men in the family with breast cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the roles of BRCA1 and 2 genes?

How can they lead to cancer development?

A
  • they are tumour suppressor genes that repair damaged DNA
  • mutations can produce pathogenic variants, which can lead to cancer developing at a younger age
    • most commonly breast and ovarian cancer, but also linked to others
  • a harmful BRCA gene can be inherited from either parent (50% chance of inheritance)
    • these are germline mutations that are present from birth in all cells of the body
  • the normal copy of the BRCA gene from the other parent can be lost or changed via a somatic alteration
  • once this has occurred, cells without any functioning BRCA1 or 2 can grow out of control and become cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are 4 important factors that must be considered in a screening programme?

A
  • the cancer should be common
  • need to be able to pick up the cancer early, allowing for early intervention
  • the tool should be user-friendly, otherwise people will not take up the screening
  • the tool should be sensitive, specific and cost-effective
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is involved in the breast screening programme?

A
  • women aged 50-70 years are offered a routine mammogram every 3 years
  • the mammogram uses XRs to identify cancers that may be too small to see or feel
  • a cancer that occurs in between these 3 year periods is an interval cancer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are some breast changes that are associated with breast cancer?

A
  • a new lump or thickening in the breast or axilla
  • a change in size, shape or feel of the breast
  • redness of the skin
  • nipple inversion
  • spontaneous nipple discharge
  • tethering of the skin (skin pulled in when arm is raised)
  • orange peel skin
  • dimpling or indentation of the skin
  • growing prominent veins
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How does the presentation of inflammatory breast cancer differ?

What is it often confused with?

A
  • a very aggressive cancer that presents with a short history of very swollen, painful, red and oedematous breasts
  • there is not usually a lump
  • it is often confused with mastitis and the patient is sent away with antibiotics
  • important to bring the patient back to ensure symptoms of mastitis have settled - if not then urgent 2WW referral
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Why does inflammatory breast cancer tend to have a worse prognosis?

A
  • it is more aggressive - it grows and spreads much faster
  • it is always at a locally advanced stage (at least stage III) when diagnosed as the breast cancer cells have grown into the skin
  • in 1 in 3 cases, it has already metastasised when diagnosed
  • it tends to occur in younger women (<40)
  • it may not show up on a mammogram, making diagnosis more difficult
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What happens after a patient has presented with symptoms or been detected through screening?

A
  • the patient attends the breast clinic for the triple assessment
  • this involves clinical examination, imaging and biopsy
  • performing all 3 of these stages results in a confident diagnosis in 99% of cases
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What questions are important to ask in the clinical examination stage of the triple assessment?

A
  • how long have the symptoms been present for?
  • any skin / nipple changes?
  • assess the symptom severity - any discharge / pain?
  • are the symptoms related to the menstrual cycle?
  • any previous breast lumps?
  • any lumps under the arm?
  • family history?
  • current medications
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the typical imaging modalities used in the triple assessment?

A

Mammography:

  • involves compression views of the breast across 2 views - oblique + craniocaudal
  • allows for detection of mass lesions or microcalcifications

Ultrasound:

  • more useful in men and women < 35 due to the dense breast tissue
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

When might CT, MRI and PET CT scans be used in breast cancer?

A
  • they are not used as part of the triple assessment
  • CT is used when there is a concern about metastases
  • PET CT is used when considering radical treatment in locally advanced disease
  • MRI is used to assess lobular breast cancers and to assess the response to neoadjuvant chemotherapy
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the 2 different methods of biopsy used in the triple assessment?

A

Fine needle aspiration cytology (FNAC):

  • this only provides cytology and is not as commonly used
  • used in women with recurrent cystic disease to relieve symptoms

Core biopsy:

  • this provides full histology, allowing differentiation between invasive and in-situ carcinoma
  • higher sensitivity and specificity compared to FNAC and can be used for tumour grading / staging
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

After performing the triple assessment, how is this scored?

A
  • at each stage, the suspicion for malignancy is graded to create an overall risk index
  • each stage is graded out of 5 depending on the likeliness of malignancy
  • the overall score is used to determine whether the patient may need further intervention
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the 2 different treatment plans for breast cancer?

What types of treatment does this involve?

A

Curative treatment:

  • aims to eradicate all disease (macro and microscopic) to provide a cure

Palliative treatment:

  • cure is not possible
  • aim is to control symptoms and improve quality of life
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the 2 different routes of curative treatment?

A

Start with surgery:

  • there is initial surgery to remove cancer within the breast and axilla
  • this is followed up with adjuvant systemic treatment to eradicate micrometastatic disease and prevent spread
  • locoregional treatment may also be required to remove microscopic disease within the breast

Wait for surgery:

  • neoadjuvant systemic treatment is given prior to surgery to downstage the tumour
18
Q

What is the aim of curative local treatment?

How is this acheived?

A

this involves surgery to remove local macroscopic disease

  • breast surgery is acheived via wide local excision or mastectomy
  • if surgeon opts for mastectomy, patient is offered reconstruction immediately or in the future
  • axillary surgery is acheived via sentinel node biopsy or axillary clearance
  • axillary clearance is performed to remove the nodes when it has already been confirmed from imaging that they contain cancer
  • sentinel node biopsy is performed to surgically stage the axilla when it is not indicated that the nodes are positive
  • sentinel node is examined to ensure there is no microscopic disease
  • if this result comes back as positive, axillary clearance or radiotherapy is required
19
Q

What is the role of adjuvant treatment in curative therapy?

What are the 2 different categories?

A

adjuvant treatment targets microscopic disease

  • the surgeon removes the breast lump, but this may have already thrown off micrometastatic disease
  • this commonly travels to the lungs, bone or liver and over time will become macrometastasis and secondary cancer
  • adjuvant treatments eradicate the micrometastasis and can be locoregional or systemic
20
Q

What is the difference between locoregional and systemic adjuvant treatment?

A

Adjuvant locoregional treatment:

  • this involves radiotherapy to remove local microscopic disease within the breast

Adjuvant systemic treatment:

  • this involves treatment in the bloodstream to remove distant microscopic disease
  • performed via chemotherapy, hormonal therapy or targeted therapy (Her2)
21
Q

What is the role of neo-adjuvant treatment in curative therapy?

What tends to be used for this?

A

this is used to down-stage the disease prior to surgery

  • needed to make definitive local curative treatment possible or to reduce the extent of local treament required
  • chemotherapy is used - especially in locally advanced disease or inflammatory breast cancer
  • ER -ve / Her2 +ve disease responds the most
22
Q

How is breast cancer staged?

A

TNM system

23
Q

What are the 3 different types of systemic treatment used in breast cancer?

A

Chemotherapy:

  • this is not very targeted and involves throwing drugs at a cancer in the hope it will damage the DNA and eradicate it

Endocrine therapy:

  • can only be used when a tumour is oestrogen sensitive (ER+)

Anti-Her2 treatment:

  • can only be used when the tumour expresses HER2 protein
24
Q

In what settings can chemotherapy be used?

What drugs are most commonly used and how do they work?

A
  • can be used in an adjuvant, neoadjuvant and palliative setting
  • EC (epirubicin and cyclophosphamide) and Docetaxel are most commonly used
  • FEC (5-FU, epi and cyclo) and Paclitaxel are sometimes used
  • oral chemotherapy with Capecitabine is used in the palliative setting
  • all these drugs work by causing DNA damage
25
Q

Why is a combination of drugs usually used in chemotherapy?

How often is it given and what factors need to be considered?

A
  • combination of drugs avoids overlapping toxicities and cross resistance
    • all drugs can be used to their full potential and will not all be toxic to the same organ
  • it is given as cycles (usually 6-8) every 3 weeks
  • need to evaluate the benefit to the patient, their general health and the risk of toxicity
26
Q

What are the general side effects associated with chemotherapy toxicity?

A
  • fatigue
  • hair loss
  • nausea and vomiting
  • mucositis
  • gastritis
  • diarrhoea / constipation
  • thrombocytopenia
  • anaemia
  • MYELOSUPPRESSION** - can result in **NEUTROPENIC SEPSIS
27
Q

What is meant by organ-specific chemotherapy toxicity?

Why is this significant?

A
  • this is usually drug-specific and is important to take into account if the patient has pre-existing comorbidities
  • many of the effects are long-term and irreversible:
    • infertility
    • secondary malignancies
    • cardiotoxicity
    • pulmonary toxicity
    • nephrotoxicity
    • neurotoxicity
28
Q

What is meant by an ER+ breast cancer?

What % of breast cancers fit into this category?

A
  • an ER+ breast cancer is “oestrogen-receptor positive”
  • the cells of the cancer have oestrogen receptors on the surface of the nucleus within the cell (lock)
  • oestrogen from the bloodstream (key) fits into these receptors and causes the breast cancer cells to grow
29
Q

What is the difference in sites of oestrogen synthesis in premenopausal and postmenopausal women?

A

Premenopausal:

  • oestrogen is produced within the ovaries

Postmenopausal:

  • the ovaries no longer produce oestrogen
  • synthesis takes place in adipose tissue, skin, liver, muscle and breast tissue
30
Q

What are the 2 different methods of action of hormonal therapies?

A
  • need to block oestrogen (key) from fitting into the oestrogen receptor (lock)
  • or block oestrogen production (premenopausal women) / extra-ovarian oestrogen production (postmenopausal women) and eradicate the key
31
Q

How does hormonal therapy work to block oestrogen production in premenopausal women?

A
  • younger women are producing large quantities of oestrogen from the ovaries
  • a surgical oophorectomy is performed to remove the ovaries
  • or a medical oophorectomy can be performed using Goserelin (Zoladex) to interrupt the pituitary-ovarian axis
  • aromatase inhibitors are given to block extra-ovarian oestrogen production from the breast, fat and adrenal glands
32
Q

How is extra-ovarian oestrogen production blocked in postmenopausal women?

A

aromatase inhibitors

  • this includes Anastrozole, Letrozole and Exemestane
  • these work by stopping the enzyme aromatase from changing other hormones into oestrogen, which can fuel the growth of breast cancer cells
  • this is the only treatment needed in postmenopausal women as the ovaries are already dead
33
Q

What hormonal therapy is used to block the oestrogen from entering the oestrogen receptor?

Who is this suitable for?

A

Tamoxifen

  • this works by competitive inhibition to seal the lock and prevent the key from entering
  • it lies on the surface of the oestrogen receptor, preventing oestrogen from entering and allowing growth of cancer cells
  • it can be used in both pre- and post-menopausal women
34
Q

What are some of the adverse effects associated with Tamoxifen?

A
  • mood changes
  • vaginal discharge
  • loss of libido
  • body image
  • endometrial changes - both benign and malignant
  • changes to periods
  • N&V
  • hot flushes / skin rashes
  • increased thrombotic risk - risk of DVT / stroke
    • if a patient on Tamoxifen becomes suddenly breathless - request CTPA and think PE
35
Q

What are the common side effects associated with aromatase inhibitors?

A
  • mood changes
  • vaginal dryness
  • loss of libido
  • body image
  • arthralgia and myalgia (can be extreme)
  • decrease in bone density
  • hot flushes / night sweats
36
Q

What is meant by a Her-2 positive breast cancer?

What % of breast cancers are accounted for by this?

A
  • the breast cancers have cells that over-express Her-2 protein
  • this is a cell-surface receptor that controls cell growth and division
  • usually each cell possesses 2 genes that encode the Her-2 protein, but gene amplification results in these cells containing many more
  • too many HER2 receptors send more signals, resulting in cells growing too quickly
  • affects 15% of all breast cancers
37
Q

What treatments are used in Her-2 +ve breast cancer?

A

Trastuzumab (Herceptin)** and **Pertuzumab

  • these are monoclonal antibodies against the Her-2 protein
  • is it NOT chemotherapy - they are antibodies that will kill the Her-2 protein and block the cell-signalling pathway
  • given IV or s/c every 3 weeks
38
Q

What are the side effects associated with Herceptin?

A
  • there is a risk of allergic reaction
  • it can be cardiotoxic, so patients need to have adequate cardiac function and this needs to be monitored during treatment
39
Q

Why and when is adjuvant radiotherapy used in breast cancer?

How is the treatment dose and number of treatments measured?

A
  • it uses high energy X-rays to kill cancer cells by causing non-repairable DNA damage
  • the treatment dose is measured in Grays (Gy)
  • the number of treatments is referred to as fractions
40
Q

What is the typical course of adjuvant radiotherapy given in breast cancer?

Why is this done?

A
  • adjuvant radiotherapy to the adjuvant breast +/- lymph node areas delivers 40 Gy in 15 fractions over 3 weeks
  • more recently, 26 Gy in 5 fractions
  • the purpose is to improve local control and reduce the risk of local relapse
41
Q

What factors can mean that someone with breast cancer has a poorer prognosis?

A
  • higher TNM stage of cancer
  • higher grade (3 > 2 > 1) / how differentiated the cancer is
  • molecular markers
    • these are proteins expressed by cancer cells detected with immunohistochemistry
  • ER negative disease
  • HER-2 positive disease
  • triple negative disease has the worst prognosis
  • age - younger women and very old women tend to have biologically bad cancers